See also this year's filing and all EDGAR filings for this company.
PDF Report 0001426332_2020_NGM_Biopharmaceuticals_INC.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'Regenerx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'RestrictedCashNoncurrent', 'DeferredCosts', 'OtherAssetsNoncurrent', 'CashAndCashEquivalentsAtCarryingValue', 'ShortTermInvestments', 'ContractWithCustomerAssetNetCurrent', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'DeferredRentCreditNoncurrent', 'ContractWithCustomerLiabilityNoncurrent', 'EarlyExercisedStockOptionsLiability', 'ConvertiblePreferredStockWarrantLiability', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DeferredRentCreditCurrent', 'ContractWithCustomerLiabilityCurrent', 'PreferredStockValue', 'StockholdersEquity', 'CommonStockValue', 'AdditionalPaidInCapitalCommonStock', 'AccumulatedOtherComprehensiveIncomeLossNetOfTax', 'RetainedEarningsAccumulatedDeficit', 'LiabilitiesConvertiblePreferredStockAndStockholdersEquityDeficit', 'CommitmentsAndContingencies', 'TemporaryEquityCarryingAmountAttributableToParent'))"} |
Graph
Absolute values for 0001426332, NGM Biopharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 355,248,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 19,475,000 |
| 3 | remainder_Assets | 5,680,000 |
| 4 | LiabilitiesCurrent | 39,718,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 9,966,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 23,631,000 |
| 9 | ResearchAndDevelopmentExpense | 129,253,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 103,544,000 |
| 12 | remainder_NetIncome | 6,545,000 |
| 13 | remainder_ComprehensiveNetIncome | 292,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 380,403,000 |
| 1 | Liabilities | 49,684,000 |
| 2 | Expenses | 152,884,000 |
| 3 | Revenues | 103,544,000 |
| 4 | StockholdersEquity | 330,719,000 |
| 5 | NetIncome | -42,795,000 |
| 6 | ComprehensiveNetIncome | -42,649,000 |
| 7 | BaseVar | 346,676,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.15 |
| 9 | EconomicCapitalRatio | 3.79 |
Edgar->Model Mapping
Feature Distribution
